98%
921
2 minutes
20
Parkinson's disease (PD) impairs balance and gait, increases fall risk, and reduces quality of life. While levodopa remains the primary treatment, it has limited effects on postural instability. Exercise training offers complementary benefits. This study examined the effects of supervised aerobic-strength exercise on postural stability and gait in PD patients, focusing on differences between ON and OFF medication states and relationships between static balance and dynamic balance during normal and dual-task walking. Fifteen PD patients completed a 4-month exercise training, with pre- and post-intervention assessments in both medication states using trunk accelerometry for static balance assessment during stance with eyes open and closed on firm and foam surfaces; and a markerless camera system for dynamic balance assessment during walking. The MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Berg Balance Scale (BBS) were utilized. Post-intervention, motor MDS-UPDRS scores improved significantly in both ON (p = 0.013) and OFF (p < 0.001) states. BBS scores increased (p = 0.005), and several postural parameters decreased in the OFF state in multiple conditions. During dual-task walking, stance time decreased in both ON (p = 0.048) and OFF (p = 0.026) states, while walking speed increased ON medication (p = 0.018). Trunk sway reduction correlated positively with stance time during dual-task walking. However, correlations between postural and gait changes without dual-task were either absent or inverse. These findings suggest that aerobic-strength exercise enhances postural stability and dual-task gait performance, particularly OFF medication. The distinct correlations between changes in postural and gait parameters indicate that specific tasks uniquely affect motor function outcomes, highlighting the need to fine-tune examination strategies in movement disorder research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12216943 | PMC |
http://dx.doi.org/10.1038/s41598-025-07009-2 | DOI Listing |
J Neural Transm (Vienna)
September 2025
Parkinson's Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, SE5 9RS, UK.
Parkinson's disease patients are at increased risk of road traffic and car accidents and those with excessive daytime sleepiness are specially susceptible. Abnormal scores on the Epworth Sleepiness Scale predicts risk for driving-related somnolence which may cause road traffic accidents in driving patients as many such patients declare dozing of while in a car. Our study estimates that over 40% of patients with daytime somnolence have risks of dozing off in a car.
View Article and Find Full Text PDFAm J Geriatr Psychiatry
August 2025
Department of Psychiatry (MLO, SEC, JZ, KS), Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Neuroimmunology Research Group (KS), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Psychiatric Program of the Netherlands Brain Bank (KS), Ne
Parkinson's disease (PD) is characterized by two neurobiological markers: pathological α-synuclein and/or a dopaminergic deficit. Depression is common in PD, and may precede motor signs, particularly in late-onset depression (LOD). We conducted two systematic reviews and a meta-analysis to examine the relationship between depression and PD development.
View Article and Find Full Text PDFParkinsonism Relat Disord
September 2025
Graduate Program in Medical Sciences, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Department of Neurology, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Electronic address:
Pract Neurol
September 2025
Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Methods Cell Biol
September 2025
Histology and Cell Biology Department, School of Medicine, Complutense University of Madrid, Madrid, Spain. Electronic address:
Parkinson disease (PD) is the second most prevalent neurodegenerative disorder globally, trailing only Alzheimer´s disease. It currently affects nearly 3 % of individuals aged 65 and above. The disease is characterized by the progressive loss of dopaminergic neurons accompanied by a chronic neuroinflammatory process, which is responsible for both motor symptoms (tremor, rigidity, bradykinesia) and non-motor symptoms (depression, dysphagia, anxiety, constipation, and anosmia).
View Article and Find Full Text PDF